Today’s Research Reports on Trending Tickers: Biocept and Myriad Genetics
U.S. equities saw losses on Wednesday, breaking a winning streak of four consecutive days, as trade tensions grew following the White House’s announcement of further tariffs on Chinese goods. The Dow Jones Industrial Average declined 0.88 percent to close at 24,700.45, while the S&P 500 Index dropped 0.71 percent to close at 2,774.02. The Nasdaq Composite Index shed 0.55 percent to close at 7,716.61.
“This is different from the other trade announcements, because the size is significantly larger, and because China is unable to directly reciprocate at $200 billion because they don’t import that much. It’s unclear what it might do next, but it is clearly another step closer to a full-blown trade war,” according to David Carter, chief investment officer at Lenox Wealth Advisors. “If the trade skirmish escalates into a full-blown trade war, that will be a bigger force in the markets than the strong fundamentals,” Carter added.
RDI Initiates Coverage on:
Myriad Genetics, Inc.
Biocept’s stock jumped 115.22% Wednesday, to close the day at $7.92. The stock recorded a trading volume of 4,650,263 shares, which was above its three months average volume of 7,868 shares. In the last year, Biocept’s shares have traded in a range of 3.50 – 1,476.00. The share price has gained 126.29% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $186.73 is below its 200-day moving average of $290.83. Shares of Biocept have fallen roughly 96.17 percent in the past month and are down 98.72 percent year-to-date.
Access RDI’s Biocept, Inc. Research Report at:
On Wednesday, shares of Myriad Genetics recorded a trading volume of 3,845,353 shares, which was above the three months average volume of 680,834 shares. The stock ended the day 13.17% higher at $43.04. The share price has fallen 2.87% from its 52 week high with a 52 week trading range of 23.28 – 44.31. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $38.12 is above its 200-day moving average of $34.00. Shares of the company are trading at a Price to Earnings ratio of 22.23. Shares of Myriad Genetics have gained roughly 10.13 percent in the past month and are up 25.3 percent year-to-date.
Access RDI’s Myriad Genetics, Inc. Research Report at:
Our Actionable Research on Biocept, Inc. (NASDAQ:BIOC) and Myriad Genetics, Inc. (NASDAQ:MYGN) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.